Objective, Quanitifed EEG-Based Neurobiological Outcomes for Evaluating Digital Mental Health Interventions

Risorius Co., Ltd. is a deep learning–based neurotechnology company developing EEG-driven biomarkers to objectively assess brain-state changes and predict prognosis in psychiatry and neurology.
We are currently conducting more than 10 retrospective clinical EEG and PSG studies, in collaboration with hospitals in Korea and other Asian countries, to establish feasibility and identify candidate neurophysiological markers linked to mental health outcomes.

Within this topic, Risorius contributes as a neurobiological outcome and early risk detection partner. Our role is to support the development and evaluation of digital mental health interventions by providing brain-level, quantitative evidence that complements behavioural, cognitive, and self-reported measures.

Within the project, we will:

• Identify EEG/PSG signatures associated with sleep disruption, emotional regulation, and vulnerability to anxiety or mood disturbances related to digital technology use

• Refine and validate candidate biomarkers longitudinally within project cohorts

• Quantify intervention-induced neurophysiological changes to support evidence-based mental health prevention strategies